New drug combo aims to shrink tough lung tumors

NCT ID NCT06448910

Ongoing Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests whether adding the immunotherapy drug cadonilimab (AK104) to standard chemoradiotherapy can improve outcomes for people with stage III non-small cell lung cancer that cannot be removed by surgery. About 41 participants will receive the drug before, during, and after radiation and chemotherapy. The study measures how many tumors shrink and tracks side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Cadonilimab (AK104) combined with chemotherapy (carboplatin/cisplatin plus etoposide) and radiation therapy
What this could lead to: If successful, this combination could offer a new treatment option that improves tumor shrinkage and delays progression for people with locally advanced lung cancer.
What could go wrong: This is a small, early-phase (Phase 2) study with only 41 participants, so results may not apply to everyone. Adding immunotherapy to chemoradiotherapy can increase side effects like lung inflammation or immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED LUNG CARCINOMA NSCLC

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.